No Data
No Data
Chongqing Taiji Industry to Buy Two Local Peers
Chongqing Taiji Industry(Group) Co.,Ltd's (SHSE:600129) Last Week's 4.1% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Chongqing Taiji Industry (600129.SH) plans to liquidate and deregister its subsidiary, Yangshengyuan Company.
Chongqing Taiji Industry (600129.SH) announced that the company will hold the tenth board meeting on December 16, 2024...
Chongqing Taiji Industry (600129.SH): plans to acquire 100% equity of its subsidiary and increase its capital.
Glory Exchange reported on December 17 that Chongqing Taiji Industry (600129.SH) announced that Tongqunge Pharmaceutical Factory, one of the pharmaceutical manufacturing enterprises under the company, intends to focus further on Operation and streamline the equity structure and management relations. The company plans to acquire 90.33% and 9.67% of the equity held by Chongqing Tongqunge Co., Ltd. (hereinafter referred to as Tongqunge shares) and Chongqing Tongqunge Chain Pharmacy Limited Liability Company (hereinafter referred to as Tongqunge Pharmacy) for a cash sum of 133.0657 million yuan and 14.2449 million yuan, respectively. After the acquisition is completed, the company will increase the cash capital of Tongqunge Pharmaceutical Factory by 32,000.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Chongqing Taiji Industry (600129.SH): Fluorouracil injection and granisetron hydrochloride injection are proposed to be selected for the national Pharmaceutical centralized procurement.
Chongqing Taiji Industry (600129.SH) released an announcement that on December 12, 2024, the company's holding subsidiary in Southwest...
No Data